Brought to you by:
PAD guideline update from ACC, AHA and others centers multispecialty care
New multisociety clinical practice guidelines for the management of lower extremity peripheral arterial disease (PAD) have been published online in the Journal of the American College of Cardiology (JACC). One of the document’s key takeaway messages is that care for…
VOYAGER PAD analyses shed light on use of rivaroxaban in high-risk patient populations
New analyses from the VOYAGER PAD clinical trial in both high-risk and fragile patients and those with and without comorbid coronary artery diseases (CAD) were presented at the American Heart Association (AHA) 2023 Scientific Sessions (Nov. 11–13) in Philadelphia. The…
Study: Combined antiplatelet, NOAC use linked to worse limb outcomes after suprainguinal bypass
A new analysis that found combined antiplatelet and novel oral anticoagulant (NOAC) therapy after suprainguinal bypass was associated with worse limb outcomes and equivalent survival compared to antiplatelet use alone has “weaknesses” but is “hypothesis-generating,” the senior author insisted during…
Digging deep into DOACs for PAD post-revascularization in fight to stave off amputation
This advertorial is sponsored by ACHL. “It’s really sad—but it’s true: In the PAD [peripheral arterial disease] space, we’re really behind. We’re behind in our understanding of the physiology, the anatomy to some extent, the way the disease permeates through the…
FDA approves two pediatric venous thromboembolism indications for rivaroxaban
The Food and Drug Administration (FDA) has approved two pediatric indications for Xarelto (rivaroxaban): the treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of…
FDA approves expanded PAD indication for rivaroxaban plus aspirin
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Food and Drug Administration (FDA) has approved an expanded peripheral arterial disease (PAD) indication for the Xarelto (rivaroxaban) vascular dose (2.5mg twice daily plus aspirin 100mg once daily) to…
VOYAGER PAD: Rivaroxaban plus aspirin should be considered after lower-extremity bypass regardless of conduit type
“A strategy of adding rivaroxaban 2.5mg twice daily to aspirin should be considered after lower extremity bypass regardless of conduit type,” concluded Nicholas Govsyeyev, MD, during the William J. von Liebig Forum at the Vascular Annual Meeting (VAM) in San…
Janssen submits new drug application to FDA for rivaroxaban to treat VTE in pediatric patients
The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced it has submitted a new drug application (NDA) to the Food and Drug Administration (FDA) for the use of Xarelto (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment…
ACC.21: VOYAGER PAD shows rivaroxaban ‘significantly’ reduced total ischemic events in PAD patients
Rivaroxaban combined with low-dose aspirin led to a significant reduction in the occurrence of total ischemic events in patients with symptomatic peripheral arterial disease (PAD) who underwent lower-extremity revascularization, according to researchers conducting the VOYAGER PAD trial. The findings were…
VOYAGER PAD: Rivaroxaban plus aspirin versus aspirin alone among CLTI patients undergoing revascularization reduced risk of adverse outcomes at three years
In one of the latest sub-analyses from the VOYAGER PAD trial, investigators found that rivaroxaban plus aspirin versus aspirin alone in the high-risk population of patients with critical limb-threatening ischemia (CLTI) undergoing lower-extremity revascularization reduced the risk of a first…